<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA approval on FinanClub</title>
    <link>https://finan.club/tags/fda-approval/</link>
    <description>Recent content in FDA approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 23 Jan 2024 09:05:47 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 23 Jan 2024 09:05:47 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:93
Chances: Merck &amp;amp; Co., Inc. continues to deliver positive news with the FDA approval of Keytruda for cervical cancer treatment. The Pharmaceutical segment of the company includes human health pharmaceutical and vaccine products, which positions it well in the current healthcare market.</description>
    </item>
    
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Thu, 28 Dec 2023 09:05:11 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:64
Chances: ImmunityBio, Inc. is participating in the 35th Annual Piper Sandler Healthcare Conference, which is a positive sign for potential collaborations and investor interest. The new data showing the potential benefits of Memory Cytokine-Enriched Natural Killer cells (M-ceNK) for patients with small cell lung cancer and other types of neuroendocrine tumors indicates promising developments in the companyâ€™s immunotherapy platform.</description>
    </item>
    
  </channel>
</rss>
